Stockwatch: Salutary lessons in drug commercialization
This article was originally published in Scrip
Last week, personalized cancer vaccine company Dendreon appeared to be in terminal decline as it struggles with low sales of its expensive product for prostate cancer, Provenge (sipuleucel-T), in the face of cheaper, more easily administered and more efficacious competition, and also with a large debt mountain. Dendreon is a rare and, you would think, salutary event in life science investing.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.